In conclusion, this study reveals that DNASE1L3 may be an important biomarker associated with immune infiltration in colon cancer and will provide a theoretical basis for the selection of immunotherapy targets for colon cancer. The gene discussed is DNASE1L3; the disease is malignant colon neoplasm.